Spero Therapeutics (SPRO) EBIAT (2016 - 2026)
Spero Therapeutics posted quarterly EBIAT of -$7.2 million for Q1 2026, up 48.05% year-on-year from -$4.9 million in Q1 2025, and down 122.89% on a QoQ basis from $31.5 million in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of EBIAT data on file, last reported at -$7.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBIAT rose 48.05% year-over-year to -$7.2 million; the trailing twelve-month figure through Mar 2026 stood at $15.2 million (up 121.78% YoY), and the FY2025 full-year result was $8.6 million, up 112.5% from the prior year.
- EBIAT for Q1 2026 stood at -$7.2 million, down from $31.5 million in the prior quarter.
- Across five years, EBIAT topped out at $51.2 million in Q4 2023 and bottomed at -$32.8 million in Q1 2022.
- The 5-year median for EBIAT is -$11.9 million (2023), against an average of -$5.3 million.
- The widest annual swing landed in 2024, when EBIAT plunged 434.38%; it then surged 250.58% in 2025.
- A 5-year view of EBIAT shows it stood at $26.8 million in 2022, then surged by 91.27% to $51.2 million in 2023, then plunged by 140.82% to -$20.9 million in 2024, then soared by 250.58% to $31.5 million in 2025, then slumped by 122.89% to -$7.2 million in 2026.
- The last three EBIAT figures came in at -$7.2 million (Q1 2026), $31.5 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.20 Mn |
| Dec 31, 2025 | 31.47 Mn |
| Sep 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -1.70 Mn |
| Mar 31, 2025 | -13.87 Mn |
| Dec 31, 2024 | -20.90 Mn |
| Sep 30, 2024 | -17.10 Mn |
| Jun 30, 2024 | -17.86 Mn |
| Mar 31, 2024 | -12.67 Mn |
| Dec 31, 2023 | 51.21 Mn |
| Sep 30, 2023 | -3.20 Mn |
| Jun 30, 2023 | -11.91 Mn |
| Mar 31, 2023 | -13.27 Mn |
| Dec 31, 2022 | 26.77 Mn |
| Sep 30, 2022 | -11.68 Mn |
| Jun 30, 2022 | -28.68 Mn |
| Mar 31, 2022 | -32.83 Mn |
| Dec 31, 2021 | -29.28 Mn |
| Sep 30, 2021 | -22.52 Mn |
| Jun 30, 2021 | -18.57 Mn |
| Mar 31, 2021 | -19.42 Mn |
| Dec 31, 2020 | -18.59 Mn |
| Sep 30, 2020 | -18.94 Mn |
| Jun 30, 2020 | -17.50 Mn |
| Mar 31, 2020 | -23.26 Mn |
| Dec 31, 2019 | -24.99 Mn |
| Sep 30, 2019 | -17.72 Mn |
| Jun 30, 2019 | -13.15 Mn |
| Mar 31, 2019 | -5.07 Mn |
| Dec 31, 2018 | -10.60 Mn |
| Sep 30, 2018 | -10.46 Mn |
| Jun 30, 2018 | -9.96 Mn |
| Mar 31, 2018 | -10.64 Mn |
| Dec 31, 2017 | -13.87 Mn |
| Sep 30, 2017 | -9.84 Mn |
| Jun 30, 2017 | -9.76 Mn |
| Mar 31, 2017 | -5.88 Mn |
| Dec 31, 2016 | -8.20 Mn |
| Sep 30, 2016 | -6.32 Mn |